The Psychedelics Newsletter

Crispin Blunt MP joins Psych Capital, Psilocybin research restrictions, Study links low serotonin and depression

Emerging Innovations in Psychedelic Healthcare, The decriminalisation of psychedelic medicines, Nearly 50% of US supports psychedelic therapy.

Small Pharma’s CEO George Tziras, ACT decriminalises psychedelic medicines, Beckley Psytech acquires Eleusis.

Washington’s Senate Bill 5660, The biosynthesis of psilocybin, DEA production quotas for 2023.

The MHRA’s Innovation Passport, Alberta to license psychedelic therapists, Clerkenwell Health raises £2.1m

Colorado’s Natural Medicine Health Act, The UK’s psychedelic healthcare ecosystem, The Economist explores psychedelic medicine.

Therapist training and psychedelic healthcare on the NHS, Psilocybin therapy for anorexia, Qualifying psychedelic research.

Biocase and psychedelic healthcare in Brazil, Royal College of Psychiatrists appeal rejection of Spravato, London as Europe's capital for psychedelic science.

Double-blind randomised clinical trials, Ketamine for treatment-resistant depression, US$900,000 grant for therapist training.

EXCLUSIVE: Angela Allbee, Oregon Psilocybin Services, Psilocybin therapy versus escitalopram, Is the psychedelic therapy bubble about to burst?

Standing on the shoulders of the Shulgins, Psilocybin therapy reduces heavy drinking days by 13%, Federally funded research to be made free to access.

The study of psilocybin in Thailand, 5.5 million in the US take psychedelic medicines, Does microdosing actually work?